Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer

Conclusion During the treatment with EGFRI, it is necessary to recognize and manage adverse reactions promptly to assure better patient quality of life and allowing continuation of therapy without dose reduction or drug discontinuation.

More here:
Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer

Related posts:

1. Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer Conclusion</b> : There is no major difference of efficacy and...
2. Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: The LABEL Study. Conclusion: Cetuximab in combination with irinotecan is active and tolerable...
3. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous… CONCLUSION: The combination of cetuximab and weekly paclitaxel was active...
4. Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and… Conclusion: Cancer patients who received cetuximab have a substantial risk...
5. The new therapy schema of the various kinds of acne based on the mucosa-skin side effects of the retinoids. Authors: Bergler-Czop B, Brzezińska-Wcisło L Abstract The most common adverse...

Leave a comment

Name (required)

E-mail (required)

URI

Your Message